Development and validation of a risk model to predict the progression of ulcerative colitis patients to acute severe disease within one year

References

• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619. doi: 10.1016/S0140-6736(12)60150-0
   PubMed Web of Science ®Google Scholar
• Sebastian S, Myers S, Nadir S, et al. Systematic review: efficacy and safety of accelerated induction regimes in infliximab rescue therapy for hospitalized patients with acute severe colitis. Dig Dis Sci. 2019 May;64(5):1119–1128. doi: 10.1007/s10620-018-5407-7
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041
   PubMedGoogle Scholar
• Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med. 2021 Sep;16(6):1433–1442. doi: 10.1007/s11739-021-02704-0
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, Vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic Science to clinical practice. J Crohns Colitis. 2020 Jun 19;14(5):694–709. doi: 10.1093/ecco-jcc/jjz195
   PubMed Web of Science ®Google Scholar
• Yoshida A, Matsuoka K, Ueno F, et al. Serum PR3-ANCA is a predictor of primary nonresponse to anti-TNF-α agents in patients with ulcerative colitis. Inflamm Intest Dis. 2021 May;6(2):117–122. doi: 10.1159/000515361
   PubMedGoogle Scholar
• Colman RJ, Dhaliwal J, Rosen MJ Predicting therapeutic response in pediatric ulcerative colitis-A journey towards precision medicine. Front Pediatr. 2021 Feb 17;9:634739. doi: 10.3389/fped.2021.634739
   PubMed Web of Science ®Google Scholar
• Monica C, Collins GS, Rönnblom A, et al. Predicting the individual risk of acute severe colitis at diagnosis.Journal of Crohn’s and colitis. Journal Of Crohn’s & Colitis. 2017;11(3):335–341. doi: 10.1093/ecco-jcc/jjw159
   PubMed Web of Science ®Google Scholar
• Akpinar MY, Ozin YO, Kaplan M, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis. J Med Biochem. 2018;37(2):155–162. doi: 10.1515/jomb-2017-0050
   PubMed Web of Science ®Google Scholar
• Hart L, Chavannes M, Kherad O, et al. Faecal calprotectin predicts endoscopic and Histological activity in clinically quiescent ulcerative colitis. J Crohns Colitis. 2020 Jan 1;14(1):46–52. doi: 10.1093/ecco-jcc/jjz107
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen B, Li Y, et al. Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study. BMC Gastroenterol. 2019 Jan 10;19(1):7. doi: 10.1186/s12876-018-0928-2
   PubMedGoogle Scholar
• Patel B, Mottola J, Sahni VA, et al. MDCT assessment of ulcerative colitis: radiologic analysis with clinical, endoscopic, and pathologic correlation. Abdom Imaging. 2012 Feb;37(1):61–9. doi: 10.1007/s00261-011-9741-x
   PubMedGoogle Scholar
• Feagins LA, Iqbal R, Spechler SJ Case-control study of factors that trigger inflammatory bowel disease flares. World J Gastroenterol. 2014;20(15):4329–34. doi: 10.3748/wjg.v20.i15.4329
   PubMed Web of Science ®Google Scholar
• Deva Rajoo G, Tan L, Lopez A, et al. Early response to corticosteroid and baseline C-Reactive protein predicts outcomes in children with Moderate to severe ulcerative colitis. Dig Dis Sci. 2019 Jul;64(7):1929–1937. doi: 10.1007/s10620-019-05486-w
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and colitis Organisation [ECCO]. Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017 Jun 1;11(6):649–670. doi: 10.1093/ecco-jcc/jjx008
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of Gastroenterology.Can J Gastroenterol.2005 Sep;19 Suppl A:5A–36A. doi: 10.1155/2005/269076
   PubMed Web of Science ®Google Scholar
• Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov145(5):987–95. doi: 10.1053/j.gastro.2013.07.024
   PubMed Web of Science ®Google Scholar
• D’Amico F, Guillo L, Baumann C, et al. Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. J Crohns Colitis. 2021;15(10):1631–1640. doi: 10.1093/ecco-jcc/jjab063
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. International organization for the study of IBD. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD: determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570–83. doi: 10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Restellini S, Chao CY, Martel M, et al. Clinical parameters correlate with endoscopic activity of ulcerative colitis: a systematic review. Clin Gastroenterol Hepatol. 2019 Jun;17(7):1265–1275.e8. doi: 10.1016/j.cgh.2018.12.021
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Institute clinical guidelines committee. AGA clinical practice guidelines on the management of Moderate to severe ulcerative colitis. Gastroenterology. 2020 Apr;158(5):1450–1461. doi: 10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016 Feb;43(4):482–513. doi: 10.1111/apt.13491
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384–413. doi: 10.14309/ajg.0000000000000152
   PubMed Web of Science ®Google Scholar
• Jonefjäll B, Simrén M, Lasson A, et al. Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. United Eur Gastroenterol J. 2018 Feb;6(1):148–158. doi: 10.1177/2050640617703868
   PubMed Web of Science ®Google Scholar
• Marti-Aguado D, Ballester MP, Tosca J, et al. Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: predictive factors of response: an observational case-control study. United Eur Gastroenterol J. 2019;7(8):1042–1050. doi: 10.1177/2050640619854277
   PubMed Web of Science ®Google Scholar
• Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021 Oct;70(10):1978–1988. doi: 10.1136/gutjnl-2021-324855
   PubMed Web of Science ®Google Scholar